J&J MedTech Reports Growth Driven by Cardiovascular Innovations and Robotics
Johnson & Johnson's MedTech division reported Q1 sales of $8.6 billion, reflecting a 4.6% increase. The company is on track to achieve $100 billion in annual revenue by 2026, bolstered by its cardiovascular portfolio and ongoing robotics development.
Theia Market Signal Identification - AI Assisted
Johnson & Johnson's MedTech division achieved sales of $8.6 billion in the first quarter, a 4.6% increase year-over-year. The company anticipates reaching $100 billion in annual revenue by 2026, driven by its cardiovascular portfolio, including the Varipulse pulsed-field ablation platform and upcoming robotic surgical programs.
J&J plans to launch two new robotic systems, Ottava and Monarch, pending FDA approval. The company also received FDA approval for the Tecnis PureSee intraocular lens, which addresses cataract-related vision loss. Despite some anticipated challenges in the second half from volume-based procurement in China, J&J remains optimistic about its growth trajectory as it focuses on higher-growth markets.
Comments